Verve Therapeutics (NASDAQ:VERV) Trading Up 10.1% - Here's What Happened

Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report)'s stock price was up 10.1% during trading on Tuesday . The stock traded as high as $6.73 and last traded at $6.66. Approximately 492,787 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 1,300,799 shares. The stock had previously closed at $6.05.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on VERV shares. Canaccord Genuity Group dropped their target price on shares of Verve Therapeutics from $30.00 to $29.00 and set a "buy" rating for the company in a research report on Monday, August 12th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Verve Therapeutics in a report on Monday, August 12th. Finally, Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $25.00 to $20.00 and set an "outperform" rating on the stock in a report on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $26.00.

Verve Therapeutics Stock Performance

The stock has a market capitalization of $535.64 million, a P/E ratio of -2.44 and a beta of 1.75. The stock's fifty day simple moving average is $5.45 and its two-hundred day simple moving average is $5.69.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.09. Verve Therapeutics had a negative net margin of 933.08% and a negative return on equity of 35.20%. The firm had revenue of $6.70 million for the quarter, compared to analyst estimates of $2.40 million. During the same period in the previous year, the firm posted ($0.87) EPS. The company's revenue for the quarter was up 219.0% compared to the same quarter last year. As a group, analysts expect that Verve Therapeutics, Inc. will post -2.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verve Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Verve Therapeutics by 15.7% during the 1st quarter. Vanguard Group Inc. now owns 6,331,312 shares of the company's stock worth $84,080,000 after acquiring an additional 859,382 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Verve Therapeutics by 8.1% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,592,198 shares of the company's stock valued at $34,424,000 after purchasing an additional 194,594 shares during the last quarter. Novo Holdings A S boosted its stake in shares of Verve Therapeutics by 20.0% in the 2nd quarter. Novo Holdings A S now owns 2,400,000 shares of the company's stock valued at $11,712,000 after purchasing an additional 400,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Verve Therapeutics by 138.1% in the 2nd quarter. Renaissance Technologies LLC now owns 474,500 shares of the company's stock valued at $2,316,000 after purchasing an additional 275,173 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Verve Therapeutics by 245.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 395,699 shares of the company's stock valued at $1,931,000 after purchasing an additional 281,173 shares during the last quarter. 97.11% of the stock is owned by institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.